2231-66-5

Usage

Uses

Used in Pharmaceutical Industry:
2,2-dimethyl-5-(1-methylethylidene)-1,3-dioxane-4,6-dione is used as a reagent in organic synthesis for the production of pharmaceutical compounds. Its high reactivity allows for the formation of various intermediates and final products, contributing to the development of new drugs and medications.
Used in Chemical Industry:
In the chemical industry, 2,2-dimethyl-5-(1-methylethylidene)-1,3-dioxane-4,6-dione is used as a precursor for the synthesis of dyes, perfumes, and flavorings. Its versatile chemical properties enable the creation of a wide range of products with different applications.
Safety Precautions:
Due to its potential for causing skin and eye irritation, 2,2-dimethyl-5-(1-methylethylidene)-1,3-dioxane-4,6-dione should be handled with care. Appropriate safety measures, such as wearing protective clothing and using eye and skin protection, should be taken to minimize the risk of exposure.

InChI:InChI=1/C9H12O4/c1-5(2)6-7(10)12-9(3,4)13-8(6)11/h1-4H3

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 109-49-9 5-Hexen-2-one 
• 75-65-0 tert-butyl alcohol 
• 67-64-1 acetone 

Downstream Products

• 81710-07-8 2,2-dimethyl-5-(1-methyl-1-phenylethyl)-1,3-dioxane-4,6-dione 
• 63364-70-5 isopropylideneketene 
• 51637-55-9 isopropenylketene 
• 67-64-1 acetone 
• 112946-26-6 carboxy(isopropenyl)ketene 
• 356535-58-5 5-(2-p-tolylpropane)-(2,2)-dimethyl-(1,3)-dioxane-4,6-dione 
• 42288-08-4 3-methyl-3-p-tolyl-butyric acid 
• 51380-85-9 3-methyl-3-p-tolyl-butyryl chloride 
• 54484-71-8 3,3,6-Trimethyl-1-indanone 
• 872791-94-1 (1-methyl-1-p-tolyl-ethyl)-malonic acid 
• 1018810-41-7 C₂₁H₂₁BrN₂O₄ 

Relevant academic research and scientific papers

A synthesis of 1-aryl-3,5-dioxo-tetrahydro-1H-pyrazols from reaction of alkyl isocyanides, isopropylidene Meldrum's acid and arylhydrazines

The reaction between alkyl isocyanides and isopropylidene Meldrum's acid in the presence of arylhydrazines leads to functionalised 1-aryl-3,5-dioxo- tetrahydro-1H-pyrazols in good yields.

Facile preparation and purification of mono tert-butyl malonate

Reaction of Meldrum's acid with tert-BuOH gives tert-BuO 2CCH2CO2H, which can be easily purified via its corresponding crystalline ammonium salt and subsequent acidification. Copyright Taylor & Francis LLC.

Alkylidene Meldrum's Acids as Platforms for the Vinylogous Synthesis of Dihydropyranones

Upon Br?nsted base organocatalysis, ketone-derived alkylidene Meldrum's acids proved to be competent vinylogous platforms able to undergo a formal (4+2) cycloaddition reaction with dihydro-2,3-furandione, providing an unprecedented route to 3,6-dihydropyran-2-ones as spiro[4.5]decane derivatives with up to 98 % ee thanks to the commercially available Takemoto catalyst. Preliminary investigation showed that this reaction could be extended to other activated ketones, establishing these alkylidene Meldrum's acids as a novel C4-synthon in the vinylogous series.

Synthesis of Cyclopentadienes for Cyclopentadienyl Ligands via Cp*RhIII-Catalyzed Formal sp3C-H Activation/Spiroannulations

An efficient Cp*RhIII-catalyzed formal C(sp3)-H activation/spiroannulation of alkylidene Meldrum's acids with alkynes has been developed using catalytical Cu(OAc)2 and air as the oxidant. This reaction demonstrates a new and straightforward approach to spirocyclopentadienes with Meldrum's acid moieties in good to excellent yields under mild reaction conditions with a broad substrate scope. Notably, this protocol provides a novel and straightforward approach to cyclopentadienes with various substitution patterns and the corresponding cyclopentadienyl-type ligands from simple substrates.

GPR40 receptor stimulant, and preparation method, pharmaceutical composition and application thereof

The invention discloses a GPR40 receptor stimulant, and a preparation method, a pharmaceutical composition and application thereof. The invention particularly discloses a GPR40 receptor stimulant shown in general formula (I) and pharmacologically acceptable salt thereof, a preparation process of the compound, a pharmaceutical composition containing the compound of general formula (I), and application of the compound and the pharmaceutical composition in anti-diabetes.

Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings

A novel series of GPR40 agonists is designed by introducing nitrogen-containing heterocyclic ring at the terminal phenyl ring of TAK-875 with the aim of decreasing its lipophilicity. Three different β-substituted phenylpropionic acids were investigated as the acidic components. A total of 34 compounds have been synthesized, among which, compound 30 exhibited comparable GPR40 agonistic activity in vitro with TAK-875 and relatively lower lipophilicity through calculation (30, EC50 = 1.2 μM, cLogP = 1.3; TAK-875: EC50 = 5.1 μM, cLogP = 3.4). Moreover, compound 30 was able to enhance the insulin secretion of primary islets isolated from normal ICR mice and showed no obvious inhibition against cytochromes P450 in vitro. In vivo, compound 30 exhibited efficacy in oral glucose tolerance test (oGTT) in normal ICR mice.

Rapid Access to Thiolactone Derivatives through Radical-Mediated Acyl Thiol-Ene and Acyl Thiol-Yne Cyclization

A new synthetic approach to thiolactones that employs an efficient acyl thiol-ene (ATE) or acyl thiol-yne (ATY) cyclization to convert unsaturated thiocarboxylic acid derivatives into thiolactones under very mild conditions is described. The high overall yields, fast kinetics, high diastereoselectivity, excellent regiocontrol, and broad substrate scope of these reaction processes render this a very useful approach for diversity-oriented synthesis and drug discovery efforts. A detailed computational rationale is provided for the observed regiocontrol.

Heterocyclic compound

The present invention relates to compound (I) or a salt thereof which has a ROR γ t inhibitory action. wherein each symbol is as defined in the specification.

HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS

Provided are heterocyclic compounds having a RORγt inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Development of a large scale asymmetric synthesis of the glucocorticoid agonist BI 653048 BS H3PO4

The development of a large scale synthesis of the glucocorticoid agonist BI 653048 BS H3PO4 (1·H3PO4) is presented. A key trifluoromethyl ketone intermediate 22 containing an N-(4-methoxyphenyl)ethyl amide was prepared by an enolization/bromine-magnesium exchange/electrophile trapping reaction. A nonselective propargylation of trifluoromethyl ketone 22 gave the desired diastereomer in 32% yield and with dr = 98:2 from a 1:1 diastereomeric mixture after crystallization. Subsequently, an asymmetric propargylation was developed which provided the desired diastereomer in 4:1 diastereoselectivity and 75% yield with dr = 99:1 after crystallization. The azaindole moiety was efficiently installed by a one-pot cross coupling/indolization reaction. An efficient deprotection of the 4-methoxyphenethyl group was developed using H3PO4/anisole to produce the anisole solvate of the API in high yield and purity. The final form, a phosphoric acid cocrystal, was produced in high yield and purity and with consistent control of particle size.